NCT00845429View on ClinicalTrials.gov

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

729

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

November 30, 2008

Conditions
InfluenzaOrthomyxovirusesMyxovirus Infection
Interventions
BIOLOGICAL

Influenza virus vaccine - cell based (2007-2008 Formulation)

0.5 mL, Intramuscular

BIOLOGICAL

Influenza virus vaccine - cell-based (2007-2008 Formulation)

1.0 mL, Intramuscular

BIOLOGICAL

Influenza virus vaccine (2007-2008 Formulation)

0.5 mL, Intramuscular

Trial Locations (15)

19020

Bensalem

27518

Cary

27609

Raleigh

29464

Mt. Pleasant

33781

Pinellas Park

35216

Hoover

36608

Mobile

45249

Cincinnati

60610

Chicago

64114

Kansas City

65802

Springfield

67207

Wichita

85710

Tucson

06460

Milford

02886

Warwick

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00845429 - Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter